| __timestamp | ImmunityBio, Inc. | Ultragenyx Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 4326000 | 10811000 |
| Thursday, January 1, 2015 | 226206000 | 33001000 |
| Friday, January 1, 2016 | 94391000 | 64936000 |
| Sunday, January 1, 2017 | 53821000 | 99909000 |
| Monday, January 1, 2018 | 35463000 | 127724000 |
| Tuesday, January 1, 2019 | 46456000 | 161524000 |
| Wednesday, January 1, 2020 | 71318000 | 182933000 |
| Friday, January 1, 2021 | 135256000 | 219982000 |
| Saturday, January 1, 2022 | 102708000 | 278139000 |
| Sunday, January 1, 2023 | 129620000 | 309799000 |
Infusing magic into the data realm
In the competitive landscape of biotechnology, understanding financial trends is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Ultragenyx Pharmaceutical Inc. and ImmunityBio, Inc. over the past decade. From 2014 to 2023, Ultragenyx's SG&A expenses surged by approximately 186%, peaking in 2023. In contrast, ImmunityBio experienced a more volatile trajectory, with a significant spike in 2015, marking a 5,130% increase from the previous year. By 2023, ImmunityBio's expenses had stabilized, showing a 2,896% increase from 2014. These trends highlight the strategic financial maneuvers each company has undertaken to navigate the biotech sector's challenges. As the industry evolves, monitoring such financial metrics will be pivotal for stakeholders aiming to gauge company performance and strategic direction.
Cost Management Insights: SG&A Expenses for Vertex Pharmaceuticals Incorporated and Ultragenyx Pharmaceutical Inc.
Comparing SG&A Expenses: Teva Pharmaceutical Industries Limited vs Ultragenyx Pharmaceutical Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Madrigal Pharmaceuticals, Inc. and ImmunityBio, Inc.
Ionis Pharmaceuticals, Inc. and ImmunityBio, Inc.: SG&A Spending Patterns Compared
Ultragenyx Pharmaceutical Inc. vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Ultragenyx Pharmaceutical Inc. vs Perrigo Company plc Trends and Insights
Selling, General, and Administrative Costs: Ultragenyx Pharmaceutical Inc. vs Taro Pharmaceutical Industries Ltd.
Cost Management Insights: SG&A Expenses for Ultragenyx Pharmaceutical Inc. and BioCryst Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? CymaBay Therapeutics, Inc. or ImmunityBio, Inc.
Who Optimizes SG&A Costs Better? Rhythm Pharmaceuticals, Inc. or ImmunityBio, Inc.
SG&A Efficiency Analysis: Comparing Veracyte, Inc. and ImmunityBio, Inc.
Breaking Down SG&A Expenses: Bausch Health Companies Inc. vs ImmunityBio, Inc.